Connect your AI

10x Genomics, Inc. TXG Change in receivables

Change in receivables at other companies

TEC

Bio-TechneTECH

$31.26M—

Other financials

Income statement

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

Market cap$4.41B+154%

Profitability

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is 10x Genomics, Inc.'s change in receivables?: 10x Genomics, Inc. (TXG) reported change in receivables of -$18.13M in Q1 2026.
What does change in receivables mean?: Change in total receivables including trade and non-trade receivables.